While IGFBP-2 is being considered as a potential tumor marker, the 14 patients in our SIRS/sepsis group with various cancers had IGFBP-2 levels similar to those without tumors (p = 0.796). Here, IGFBP2 is linked to systemic inflammatory response syndrome.